iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 2097

Identifiers

  • Canonical SMILES:
    CC[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CNC(=O)[C@H](NC1=O)c1ccccc1)NC(=O)C(C)C
  • IUPAC name:
    N-[(3R,6S,9S,12R)-9-(3-carbamimidamidopropyl)-6-ethyl-2,5,8,11-tetraoxo-3-phenyl-1,4,7,10-tetraazacyclotridecan-12-yl]-2-methylpropanamide
  • InChi:
    InChI=1S/C25H38N8O5/c1-4-16-21(35)33-19(15-9-6-5-7-10-15)24(38)29-13-18(32-20(34)14(2)3)23(37)31-17(22(36)30-16)11-8-12-28-25(26)27/h5-7,9-10,14,16-19H,4,8,11-13H2,1-3H3,(H,29,38)(H,30,36)(H,31,37)(H,32,34)(H,33,35)(H4,26,27,28)/t16-,17-,18+,19+/m0/s1
  • InChiKey:
    HITKRNXBNHCNTJ-INDMIFKZSA-N

External links


137630040

CHEMBL4116447

External search

Bibliography (1)

Publication Name
Karatas Hacer, Li Yangbing, Liu Liu, Ji Jiao, Lee Shirley, Chen Yong, Yang Jiuling, Huang Liyue, Bernard Denzil, Xu Jing, Townsend Elizabeth C., Cao Fang, Ran Xu, Li Xiaoqin, Wen Bo, Sun Duxin, Stuckey Jeanne A, Lei Ming, Dou Yali, Wang Shaomeng. . Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction Journal of Medicinal Chemistry. 9

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
2 0 0 0

Targets

PPI family Best activity Diseases MMoA
WDR5/MLL 6.62 lymphoid leukemia (disease) Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 530.30 g/mol
HBA 13
HBD 9
HBA + HBD 22
AlogP -1.80
TPSA 209.14
RB 8
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 2 0 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1021/acs.jmedchem.6b01796 9 KMT2A
Q03164
WDR5
P61964
Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 5.92
10.1021/acs.jmedchem.6b01796 9 KMT2A
Q03164
WDR5
P61964
Biochemical assay Fluorescence Polarization pKi (inhibition constant, -log10) 6.62
Ta Structure Name Drugbank ID
0.6822 CR665 DB05155
0.6757 D-phenylalanyl-N-benzyl-L-prolinamide DB07143
0.6525 D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide DB07005
0.6522 D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide DB07133
0.6508 Cilengitide DB11890
0.6488 Chymostatin DB01683
0.6364 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06947
0.6364 D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06996
0.6350 Argifin DB03632
0.6320 Neocitrullamon DB13396
0.6302 D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide DB07027
0.6277 Brimapitide DB15231
0.6250 D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide DB06919
0.6216 (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide DB06845
0.6182 1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06929